Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jon I Williams"'
Publikováno v:
Clinical Ophthalmology.
Phillip J Buckhurst,1 George Lau,2 Jon I Williams,2 Mark Packer3 1School of Health Professions, University of Plymouth, Plymouth, UK; 2Bausch and Lomb Surgical, Bausch and Lomb Bridgewater, New Jersey, NJ, USA; 3Mark Packer Consulting, Boulder, CO, U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::140172d0b0081eb36278ad4011d101ef
https://www.dovepress.com/efficacy-of-a-one-piece-aberration-neutral-hydrophobic-acrylic-toric-i-peer-reviewed-fulltext-article-OPTH
https://www.dovepress.com/efficacy-of-a-one-piece-aberration-neutral-hydrophobic-acrylic-toric-i-peer-reviewed-fulltext-article-OPTH
Autor:
Amar Agarwal, Timothy T. You, Dhivya Ashok Kumar, Sherif A. Shaarawy, Anusha Venkataraman, Richard S. Hope, Jon I Williams, Paulo E. Stanga
Publikováno v:
Retina (Philadelphia, Pa.)
This is a first-in-human study using a new hypersonic vitrectomy technology, a promising new alternative to the currently commercially available guillotine vitrectors. This study shows the initial experience in humans and highlights potential benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed4a4b6250d7505b1aff7363a5c09dd
https://doi.org/10.1097/iae.0000000000002365
https://doi.org/10.1097/iae.0000000000002365
Publikováno v:
Journal of Cataract and Refractive Surgery. 44:1220-1229
To assess the safety and efficacy of a 0.38% submicron formulation of loteprednol etabonate (LE) gel for the treatment of postoperative inflammation and pain after cataract surgery.Forty-five United States ophthalmology practices.Double-masked vehicl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c64a1c72bdde5be72d64776ed9f8a20
https://doi.org/10.1016/j.jcrs.2018.06.056
https://doi.org/10.1016/j.jcrs.2018.06.056
Publikováno v:
Clinical Ophthalmology.
Mark Packer,1 Jon I Williams,2 Gregg Feinerman,3 Richard S Hope2 On behalf of the enVista Toric Clinical Study Group 1Mark Packer MD Consulting, Inc., Boulder, CO, USA; 2Surgical Clinical and Medical Affairs, Bausch & Lomb Inc., Irvine, CA, USA; 3Fei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::446689bd1a026c0692c53f272f8850f3
https://www.dovepress.com/prospective-multicenter-clinical-trial-to-evaluate-the-safety-and-effe-peer-reviewed-article-OPTH
https://www.dovepress.com/prospective-multicenter-clinical-trial-to-evaluate-the-safety-and-effe-peer-reviewed-article-OPTH
Autor:
Jon I. Williams, Kathryn S. Kennedy, James A. Gow, Gail L. Torkildsen, Mark B. Abelson, Paul J. Gomes, Timothy R. McNamara, for the Bepotastine Besil
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 27:385-393
This clinical trial evaluated the safety and effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo for the treatment of ocular itching and conjunctival hyperemia (redness) using the conjunctival allergen chall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea58800cf5860c719cf106929bee9865
https://doi.org/10.1089/jop.2011.0005
https://doi.org/10.1089/jop.2011.0005
Autor:
Mark B, Abelson, Gail L, Torkildsen, Jon I, Williams, James A, Gow, Paul J, Gomes, Timothy R, McNamara
Publikováno v:
Clinical Therapeutics. 31:1908-1921
Bepotastine besilate is a highly selective histamine H(1)-receptor antagonist with antihistaminic, mast cell stabilizing, and anti-inflammatory activity. Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe661cc73555fe8b581c4ae33fa2f183
https://doi.org/10.1016/j.clinthera.2009.09.001
https://doi.org/10.1016/j.clinthera.2009.09.001
Autor:
Mina K. Gabriel, Michael D. Swerdloff, Raymond J. Brambilla, Susan B. Anderson, Jon I. Williams, R. Donald Sedgwick, David M. Hindenlang
Publikováno v:
International Journal of Peptide and Protein Research. 33:318-327
Several decapeptides related to consensus peptide sequences found in the natural polyphenolic proteins from the sea mussels M. edulis or M. californianus have been synthesized in high yields and purities. The peptides were prepared by solid phase pep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70e7c7e43152e161201b56bf7cc50150
https://doi.org/10.1111/j.1399-3011.1989.tb00688.x
https://doi.org/10.1111/j.1399-3011.1989.tb00688.x
Autor:
Warner W. Carr, Anjuli S. Nayak, Paul H. Ratner, James A. Gow, Timothy R. McNamara, Jon I. Williams, null for the Bepotastine Besilate Ophthalmic Solut
Publikováno v:
Allergy and asthma proceedings. 34(3)
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the Western world, with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a dual-acting histami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7621eb2eec0b033d40482e588f4037da
https://pubmed.ncbi.nlm.nih.gov/23484763
https://pubmed.ncbi.nlm.nih.gov/23484763
Autor:
Edward J. Meier, Gail L. Torkildsen, James A. Gow, Timothy R. McNamara, Paul J. Gomes, Jon I. Williams, null for the Bepotastine Besilate Ophthalmic Solut
Publikováno v:
Allergy and asthma proceedings. 33(3)
Allergic conjunctivitis is a clinical reaction to environmental allergens and is manifested by ocular itching caused by IgE-induced mast cell degranulation. Bepotastine besilate is a selective H(1)-antagonist with mast cell stabilizing properties. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab4e0d3224342d18d1e814bae564e6a
https://pubmed.ncbi.nlm.nih.gov/22991696
https://pubmed.ncbi.nlm.nih.gov/22991696
Autor:
Jon I. Williams
Publikováno v:
Antiangiogenic Agents in Cancer Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa82d8c4c40d3814912b771a86e7751
https://doi.org/10.1385/0-89603-641-3:153
https://doi.org/10.1385/0-89603-641-3:153
